



Date: January 21, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of Company at its meeting held on January 21, 2022, has, inter alia, considered and approved the Unaudited Financial Results of the for the Quarter and nine months ended December 31, 2021 along with the Limited Review Report.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (Listing Regulations), we are enclosing a copy of the above mentioned Unaudited Financial Results along with the Limited Review Report of the Auditors.


The Financials Results will be published in newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 12.25 p.m.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,
For Supriya Lifescience Limited


Shweta Singh

Company Secretary & Compliance Officer
Membership No.: A44973



Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063. Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011

CIN: U51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist.-Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

SUPRIYA LIFESCIENCE LIMITED
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: U51900MH2008PLC180452
Tel No.: +91 22 40332727; E-mail: supriya@supriyalifescience.com; Website: www.supriyalifescience.com
UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2021

Rs. in Millions, except per share data

Part I - Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months Ended 31st December, 2021

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Nine Months	Nine Months Ended	Year ended
		31-12-2021	30-09-2021	31-12-2020	Ended 31-12-2021	31-12-2020	31-03-2021
		Unaudited*	Unaudited*	Unaudited*	Unaudited*	Unaudited*	Audited*
	Income						
I	Revenue from Operations	1,170.00	1,480.06	806.91	3,418.00	2,557.17	3,853.66
II	Other Income	54.42	31.73	43.29	107.02	106.01	108.56
III	Total Income	1,224.41	1,511.80	850.20	3,525.02	2,663.18	3,962.21
2	Expenses						
	a) Cost of Materials Consumed	722.27	464.36	421.98	1,605.88	990.75	1,405.71
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods, work in progress & stock in trade.	-304.35	-28.22	-94.43	-356.15	-6.67	-124.45
	d. Employee benefit expenses	184.29	94.04	107.64	362.09	234.72	327.61
	e. Finance Cost	11.49	10.58	8.14	31.81	65.44	40.80
	f. Depreciation & amortisation expense	25.99	24.63	47.91	75.39	49.77	67.61
	g. Other expenditure	184.03	168.87	113.43	488.36	312.49	571.83
IV	Total Expenses	823.72	734.26	604.67	2,207.37	1,646.51	2,289.11
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	400.70	777.54	245.53	1,317.65	1,016.67	1,673.10
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	-	-	-	-	-	-
VIII	Tax Expense						
	a) Current Tax	124.16	197.23	85.12	337.44	255.37	430.22
	b) Deferred Tax	-119.86	-1.90	3.48	-75.79	10.44	6.94
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	396.40	582.20	156.93	1,055.99	750.86	1,235.93
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	396.40	582.20	156.93	1,055.99	750.86	1,235.93
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-5.27	-0.56	-0.75	-5.77	-2.25	-1.66
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	1.33	0.14	0.19	1.45	0.57	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	-3.94	-0.42	-0.56	-4.32	-1.68	-1.24
XVI	Earnings per equity Share (for continuing operation):						
	(1) Basic	4.93	7.96	2.14	13.12	10.26	16.89
	(2) Diluted	4.93	7.96	2.14	13.12	10.26	16.89
XVII	Earnings per equity Share (for discontinued operation):						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
	(1) Basic	4.93	7.96	2.14	13.12	10.26	16.89
	(2) Diluted	4.93	7.96	2.14	13.12	10.26	16.89



